Poniard Pharmaceuticals, Inc. (MM) News - PARD

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Poniard Pharmaceuticals Reports Third Quarter 2011 Financial Results

SAN FRANCISCO, CA -- (Marketwire) -- 10/28/11 -- Poniard Pharmaceuticals, Inc. (NASDAQ: PARD), a biopharmaceutical company focused on innovative...

- Quarterly Report (10-Q)

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ...

- Filing of certain prospectuses and communications in connection with business combination transactions (425)

Filed by Poniard Pharmaceuticals, Inc. pursuant to Rule 425 under the Securities Act of 1933, as amended...

Egan-Jones Recommends Poniard Shareholders Vote "FOR" Poniard's Proposed Merger With ALLOZYNE and Reverse Stock Split

SAN FRANCISCO, CA -- (Marketwire) -- 10/28/11 -- Poniard Pharmaceuticals, Inc. (NASDAQ: PARD) announced today that Egan-Jones Proxy Services, an...

- Filing of certain prospectuses and communications in connection with business combination transactions (425)

Filed by Poniard Pharmaceuticals, Inc. pursuant to Rule 425 under the Securities Act of 1933, as amended...

- Additional Proxy Soliciting Materials (definitive) (DEFA14A)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A...

- Current report filing (8-K)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT...

- Filing of certain prospectuses and communications in connection with business combination transactions (425)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT...

- Prospectus filed pursuant to Rule 424(b)(3) (424B3)

Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-175778 We are...

Registration Effectiveness Orders Issued By The SEC

The following table includes registration statements and post-effective amendments that were declared effective by the Securities and Exchange...

- Notice of Effectiveness (EFFECT)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 NOTICE OF EFFECTIVENESS Effective Date: October 07, 2011 Form:...

Poniard Pharmaceuticals Announces Effectiveness of Form S-4 Registration Statement for the Proposed Merger with ALLOZYNE

SAN FRANCISCO, CA -- (Marketwire) -- 10/07/11 -- Poniard Pharmaceuticals, Inc. (NASDAQ: PARD), a biopharmaceutical company focused on innovative...

- Statement of Changes in Beneficial Ownership (4)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction...

- Filing of certain prospectuses and communications in connection with business combination transactions (425)

Filed by Poniard Pharmaceuticals, Inc. pursuant to Rule 425 under the Securities...

- Confidential Treatment Order (CT ORDER)

workyourmoney 11 years ago

OK, what's up with the jump? No news stories anywhere?

👍️0

Attote 12 years ago

Any news from PARD...?

👍️0

rodneys 12 years ago

They invested more than 100 million and they have a few results:

Poniard Pharmaceuticals Announces Updated Positive Clinical Data from Phase 2 Trial of Picoplatin in Colorectal Cancer and New Phase 1 Cardiac Safety Trial Results

Poniard Pharmaceuticals, Inc. (PARD) has received Clinical Trial Application (CTA) approval from the Chinese State Food and Drug Administration (SFDA) to conduct two Phase III clinical studies of its lead product candidate, picoplatin, in the treatment of second-line small cell lung cancer (SCLC) and second-line ovarian cancer in the People's Republic of China.

VSTM paid Poniard an upfront license fee and agreed to pay Poniard milestone payments of up to an aggregate of $13,250,000 upon the achievement of specified development and regulatory milestones.

And yes it’s gambling you do !! I own 13.500 shares av. 1.09. and hope to sell them for at least 1.50.

👍️0

Attote 12 years ago

If I do not think that the products are sold alone ... very strange that, cres not you ...? or your door opens by itself?
And the costs of goods do not exist?, Think what you say makes no sense.

👍️0

christiane 12 years ago

2 employees = little cost.

But they have a lot of products they can sell.

👍️0

Attote 12 years ago

As can be optimistic with a company that has no employees and no revenue ..?

👍️0

rodneys 12 years ago

http://www.mysmartrend.com/news-briefs/news-watch/telik-among-companies-biotechnology-industry-lowest-beta-telk-rosg-pard-rgen-

http://www.americanbulls.com/StockPage.asp?CompanyTicker=PARD&MarketTicker=OTC&Typ=S

http://www.deepmarket.com/stock/pard

👍️0

rodneys 12 years ago

Every day we go a little bit higher.
0.56 0.05 +9.55%

I expect $1 before the end of september.

👍️0

rodneys 12 years ago

0.57 +0.11(+23.48%)

I expect big news before the end of the year.

High volume and:
PARD is trading in the range of $0.40 - $0.60 in the past 15 days.
Commodity Channel Index (CCI) is bullish for PARD.
PARD formed a bullish 5-day exponential moving average and 9-day exponential moving average crossover.
PARD formed a bullish Price & Exponential Moving Average Crossover signal.
PARD formed a bullish Price & Simple Moving Average Crossover signal.
PARD formed a bullish 5-day simple moving average and 10-day simple moving average crossover.
Our rating on the stock: VERY BULLISH with a score of 5/5.

P.S. I own 13.500 shares av. 1.09.

jhnvtjll 12 years ago

You're welcome.

👍️0

Attote 12 years ago

Thanks a lot,i have over 10000$,loosing 60%.I send to them a email,and no body replay me.Thank,again, to you.

👍️0

jhnvtjll 12 years ago

Company terminated all of its employees on March 30, 2012, and has ceased substantially all of its operations.

From Form 8-K:
"The Company plans to seek short-term financing, which may be from a related party, to support minimal operations while the Company explores alternative sources of financing in order to continue its efforts to enter into an arrangement to support the continued development of its picoplatin product candidate."

👍️0

Attote 12 years ago

Some one knows what happend with company...??

👍️0

surf1944 13 years ago

No loger short PARD, watching it for now.....

👍️0

surf1944 13 years ago

PARD was a great short on the price spike in Nov.

👍️0

pennystockingz 13 years ago

This looks like its ready 2 bounce.

http://stockcharts.com/h-sc/ui?s=pard

👍️0

BigWool 13 years ago

What's going on?

PARD $ 2.1395 ?-0.3605 (-14.42%)

👍️0

mlkrborn 13 years ago

Poniard Pharma (PARDD) and Allozyne terminate planned merger (PARD) 2.95 : Co announced that Poniard (PARDD) and Allozyne have mutually agreed to terminate the Agreement and Plan of Merger and Reorganization dated June 22, 2011. The termination follows the parties' determination that the common stock of the combined company resulting from the proposed merger will not qualify for listing on The Nasdaq Capital Market, which is a condition to closing of the merger. Poniard's board of directors is actively exploring alternatives for Poniard's business and assets.

👍️0

BigWool 13 years ago

Still think selling is tax based...?

👍️0

BigWool 13 years ago

No merger... all the hustle and bustle for nothing, uh....?

Poniard Pharmaceuticals and Allozyne Terminate Planned Merger

SAN FRANCISCO, CA, Dec 22, 2011 (MARKETWIRE via COMTEX) --Poniard Pharmaceuticals, Inc. (NASDAQ: PARDD) today announced that Poniard and Allozyne, Inc. have mutually agreed to terminate the Agreement and Plan of Merger and Reorganization dated June 22, 2011. The termination follows the parties' determination that the common stock of the combined company resulting from the proposed merger will not qualify for listing on The Nasdaq Capital Market, which is a condition to closing of the merger. Poniard's board of directors is actively exploring alternatives for Poniard's business and assets.

About Poniard Pharmaceuticals

Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative oncology products. For additional information please visit http://www.poniard.com.

For Further Information:

Media:
David Pitts
Argot Partners
(212) 600-1902
Email Contact

👍️0

TARKA2 13 years ago

Thank you!
Happy New Year 2012!!

👍️0

surf1944 13 years ago

Tax loss selling season until the end of next week, bottom, there may be no bottom until then.

What's the real value after this merger??
Have you figger it out?

👍️0

surf1944 13 years ago

PARD likely going lower with tax loss selling a down market into Jan.

👍️0

TARKA2 13 years ago

Never a rebound? Where's the botom???

👍️0

TARKA2 13 years ago

Down she go. No hope here?

👍️0

TARKA2 13 years ago

What happens with the PPS after the Merger with ..... ???

👍️0

kraken17 13 years ago

PARDD now, 6.26$, chart in
http://stockcharts.com/h-sc/ui?s=pardd

👍️0

H town Dag 13 years ago

PARDD

👍️0

kraken17 13 years ago

which is the new ticker/name after the R/S?

👍️0

mlkrborn 13 years ago

Poniard Pharma announces shareholders approve merger with Allozyne (PARD) 0.22 -0.04 : Co announced that its shareholders have approved proposals to complete the previously announced merger with Allozyne including the issuance of shares of Poniard common stock and resulting change of control of Poniard resulting from the merger and effecting a 1-for-40 reverse stock split of Poniard common stock.

👍️0

DeadCellShadix 13 years ago

The early morning is looking good so far..

👍️0

DeadCellShadix 13 years ago

It will be interesting to see where this one goes tomorrow..

👍️0

guitartattooman 13 years ago

Momentum Gapper on Monday!

👍️0

Pennyprof 13 years ago

That's right, the vote is on Nov. 21st. Looking through the last quarterly report, this isn't the first time this year they've voted to do a R/S. They didn't have enough votes last time...
I doubt it will happen again as the merger with Allozyne is depending on regaining compliance with Nasdaq regulations.

"The Company adjourned its reconvened annual meeting of shareholders on July 22, 2011, with an insufficient number of votes to approve the reverse stock split proposal. Although 91.6% of the shareholders who voted at the annual meeting voted in favor of the reverse stock split proposal, those shareholders held only 49.2% of the Company’s common stock outstanding and entitled to vote. A majority (50% plus one share) of the Company’s common stock outstanding and entitled to vote was required to approve the reverse stock split proposal. On July 19, 2011, the Company received a letter from the Staff advising that the Company has not regained compliance with the $1.00 per share minimum bid price requirement of Nasdaq Listing Rule 5550(a)(2) and, unless the Company requests an appeal of this determination, the Company’s common stock would be delisted from The Nasdaq Capital Market. On August 25, 2011, representatives of the Company attended a hearing to appeal the Staff decision and to present a plan for compliance. On September 2, 2011, the Nasdaq Hearings Panel determined to allow the continued listing of the Company’s common stock on The Nasdaq Capital Market subject to the conditions that, on or before December 31, 2011, the Company must have (i) held a shareholders’ meeting; (ii) obtained shareholder approval for the merger ."

👍️0

moores2009 13 years ago

I think monday is when they vote to decide if the r/s is the way they want to go. could be wrong though, I just skimmed through it friday.

👍️0

thinkdifferent 13 years ago

Even if the R/S goes thru, its not bad thing for this company as I believe its priced in already. They are doing it to acquire or merge with allozyne. It's not a usual .r/s. Two things you should consider, the current market cap of Pard and the people coming onboard, not to forget, a drug similar to biogen.Although we could be pleasantly surprised if there is more news and we get above a dollar without a reverse split.

👍️0

hondaboost 13 years ago

PARD, 1 for 40 R/S news:

PR released on Nov 7:

SAN FRANCISCO, CA--(Marketwire -11/07/11)- Poniard Pharmaceuticals, Inc. (NASDAQ: PARD - News) announced today that Glass, Lewis & Co., a leading independent proxy advisory firm, has recommended that Poniard shareholders vote "FOR" all proposals listed in the Company's proxy statement materials, including the proposal related to the issuance of stock in connection with Poniard's proposed merger with ALLOZYNE, Inc. and the proposal to effect a 1-for-40 reverse stock split of Poniard's outstanding common stock.

👍️0

jason90 13 years ago

$PARD looking like it could gap on Monday, some short selling at the end.

👍️0

The Poor Little Rich Boy 13 years ago

How long have you been following the story? There is so much more to it than just that. The 10000 shares is of a non-operating entity with intellectual property, They are planning a reverse merger with a much larger privately owned corporation of unkown value, and deep pockets. PARD shareholders will retain 35% of the new company. In order to stay listed on nasdaq market, the share price has to come back above a certain level, and a reverse split will bring the share price to that level. Cry dilution if you like, but that's not what is going on here. The Intellectual property of Poniard is valuable, they just didn't have the money burn that it requires to get their products through the regulatory process. Now they have a new partner, and the partner has the resources that is necessary to get things moving. Not only that, but the new partner desires to be publicly traded. 35% Is much greater than average. The new partner has an entire pipeline of product candidates of its own as well. Things are looking up for good old Poniard Pharmaceuticals.

👍️0

The_Shadow 13 years ago

When did they announce a reverse split?

👍️0

TheReign 13 years ago

couldn't break .30 after it fell below it from the HOD. hope it pops monday.

👍️0

hondaboost 13 years ago

Your 10k shares will go to 250 shares, with 1 for 40 Huge Reverse split.

👍️0

The_Shadow 13 years ago

these tiny sells keep knocking it down! frustrating

The_Shadow 13 years ago

blast through .30

👍️0

hondaboost 13 years ago

PARD, What a joking $250k payment! Will do 1 for 40 Reverse Split, Huge!!!

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

Poniard Pharmaceuticals, Inc. (MM) (PARD)

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

PARD News

Poniard Pharmaceuticals Reports Third Quarter 2011 Financial Results

- Quarterly Report (10-Q)

- Filing of certain prospectuses and communications in connection with business combination transactions (425)

Egan-Jones Recommends Poniard Shareholders Vote "FOR" Poniard's Proposed Merger With ALLOZYNE and Reverse Stock Split

- Filing of certain prospectuses and communications in connection with business combination transactions (425)

- Additional Proxy Soliciting Materials (definitive) (DEFA14A)

- Current report filing (8-K)

- Filing of certain prospectuses and communications in connection with business combination transactions (425)

- Prospectus filed pursuant to Rule 424(b)(3) (424B3)

Registration Effectiveness Orders Issued By The SEC

- Notice of Effectiveness (EFFECT)

Poniard Pharmaceuticals Announces Effectiveness of Form S-4 Registration Statement for the Proposed Merger with ALLOZYNE

- Statement of Changes in Beneficial Ownership (4)

- Filing of certain prospectuses and communications in connection with business combination transactions (425)

- Confidential Treatment Order (CT ORDER)

PARD Discussion

Your Recent History

Company

Business

Popular

Get The App

Trending Now

Toplists

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

Poniard Pharmaceuticals, Inc. (MM) (PARD) News

Poniard Pharmaceuticals, Inc. (MM) (PARD)

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

PARD News

Poniard Pharmaceuticals Reports Third Quarter 2011 Financial Results

- Quarterly Report (10-Q)

- Filing of certain prospectuses and communications in connection with business combination transactions (425)

Egan-Jones Recommends Poniard Shareholders Vote "FOR" Poniard's Proposed Merger With ALLOZYNE and Reverse Stock Split

- Filing of certain prospectuses and communications in connection with business combination transactions (425)

- Additional Proxy Soliciting Materials (definitive) (DEFA14A)

- Current report filing (8-K)

- Filing of certain prospectuses and communications in connection with business combination transactions (425)

- Prospectus filed pursuant to Rule 424(b)(3) (424B3)

Registration Effectiveness Orders Issued By The SEC

- Notice of Effectiveness (EFFECT)

Poniard Pharmaceuticals Announces Effectiveness of Form S-4 Registration Statement for the Proposed Merger with ALLOZYNE

- Statement of Changes in Beneficial Ownership (4)

- Filing of certain prospectuses and communications in connection with business combination transactions (425)

- Confidential Treatment Order (CT ORDER)

PARD Discussion

Your Recent History

Company

Business

Popular

Get The App